الفهرس 
IntroductionOnly 14 pages are availabe for public view
Abstract
C
hest CT is a supportive device for diagnosing and observing disease progression such as COVID-19. Reporting and Data system (CO-RADS) grades that according to level of suspicion for pulmonary involvement based on the CT chest features seen where it is divided into four groups from very low (CORADS category 1) to very high (CO-RADS category 5) (Fang et al., 2020).
SARS-CoV-2 can enter angiotensin converting enzyme II (ACE2)-expressing cells. ACE2 is expressed in several areas including the lung alveolar type 2 cells, upper esophagus, in stratified epithelial cells and absorptive enterocytes in the ileum and colon.
The enteric symptoms of SARS-CoV-2 may be associated with invaded ACE2-expressing enterocytes. These findings suggest that the digestive system, along with the respiratory tract, may be a potential route for SARS-CoV-2 infection, and could explain why some patients present with gastrointestinal symptoms (Luo et al., 2020).
Early detection and isolation of suspicious cases decrease disease spread at the time of a pandemic. We found that sensitivity is far more important than specificity. To increase the diagnostic accuracy of chest CT, some guidelines suggested combining chest CT with other tests (Guan et al., 2020).
Adding more that the present evidence suggest that radiologists should have a high index of suspicion with respect to the lungs in patients presenting with primary non-pulmonary clinical symptoms who did non CT chest studies to facilitate earlier diagnosis of coronavirus disease related pneumonia during the current pandemic. These manifestations prove that typical pulmonary findings of COVID 19 at the upper and lower margins of the scan are most commonly peripheral GGO followed by consolidation (Hossain et al., 2020).
Overall identification of COVID-19 infection should depend on judicious interpretation of clinical, radiological, laboratory and RT-PCR. However possibility of COVID 19 should be always on mind in patients presenting primarily with non-chest symptoms’ and can be screened by at least CT Chest as a primary protective measure (Kovács et al., 2021).